Brought to you by 
Ablynx signs exclusive Nanobody deal with Wyeth; terminated
03 Aug 2020
Executive Summary
Ablynx (therapeutic antibodies) licensed Wyeth Pharmaceuticals exclusive global rights to develop and commercialize Nanobodies targeting the tumor necrosis factor alpha protein and its receptors for use in treating various diseases such as rheumatoid arthritis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ablynx signs exclusive Nanobody deal with Wyeth; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice